| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection JF Salazar-Gonzalez, MG Salazar, BF Keele, GH Learn, EE Giorgi, H Li, ... Journal of Experimental Medicine 206 (6), 1273-1289, 2009 | 962 | 2009 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 907 | 2022 |
| Subcutaneous REGEN-COV antibody combination to prevent Covid-19 MP O’Brien, E Forleo-Neto, BJ Musser, F Isa, KC Chan, N Sarkar, KJ Bar, ... New England Journal of Medicine 385 (13), 1184-1195, 2021 | 465 | 2021 |
| Effect of HIV antibody VRC01 on viral rebound after treatment interruption KJ Bar, MC Sneller, LJ Harrison, JS Justement, ET Overton, ME Petrone, ... New England Journal of Medicine 375 (21), 2037-2050, 2016 | 465 | 2016 |
| High multiplicity infection by HIV-1 in men who have sex with men H Li, KJ Bar, S Wang, JM Decker, Y Chen, C Sun, JF Salazar-Gonzalez, ... PLoS pathogens 6 (5), e1000890, 2010 | 345 | 2010 |
| Wide variation in the multiplicity of HIV-1 infection among injection drug users KJ Bar, H Li, A Chamberland, C Tremblay, JP Routy, T Grayson, C Sun, ... Journal of virology 84 (12), 6241-6247, 2010 | 269 | 2010 |
| Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated HX Liao, X Chen, S Munshaw, R Zhang, DJ Marshall, N Vandergrift, ... Journal of Experimental Medicine 208 (11), 2237-2249, 2011 | 252 | 2011 |
| Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape KJ Bar, C Tsao, SS Iyer, JM Decker, Y Yang, M Bonsignori, X Chen, ... PLoS pathogens 8 (5), e1002721, 2012 | 221 | 2012 |
| Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting B Julg, L Dee, J Ananworanich, DH Barouch, K Bar, M Caskey, DJ Colby, ... The lancet HIV 6 (4), e259-e268, 2019 | 168 | 2019 |
| C-terminal Heparin Binding Domain BA Booth, M Boes, DL Andressit, BL Dake, MC Kieferț, C Maack, ... Growth Regulation 5, 1-17, 1995 | 162 | 1995 |
| Recommendations for measuring HIV reservoir size in cure-directed clinical trials M Abdel-Mohsen, D Richman, RF Siliciano, MC Nussenzweig, BJ Howell, ... Nature medicine 26 (9), 1339-1350, 2020 | 111 | 2020 |
| HIV-1 latent reservoir size and diversity are stable following brief treatment interruption DB Salantes, Y Zheng, F Mampe, T Srivastava, S Beg, J Lai, JZ Li, ... The Journal of clinical investigation 128 (7), 3102-3115, 2018 | 111 | 2018 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 98 | 2022 |
| Transplanting hepatitis C virus–infected hearts into uninfected recipients: a single-arm trial RC McLean, PP Reese, M Acker, P Atluri, C Bermudez, LR Goldberg, ... American Journal of Transplantation 19 (9), 2533-2542, 2019 | 98 | 2019 |
| CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption J Harper, S Gordon, CN Chan, H Wang, E Lindemuth, C Galardi, ... Nature medicine 26 (4), 519-528, 2020 | 82 | 2020 |
| Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome H Song, JW Pavlicek, F Cai, T Bhattacharya, H Li, SS Iyer, KJ Bar, ... Retrovirology 9, 1-14, 2012 | 76 | 2012 |
| Predictors of nonseroconversion after SARS-CoV-2 infection W Liu, RM Russell, F Bibollet-Ruche, AN Skelly, S Sherrill-Mix, ... Emerging Infectious Diseases 27 (9), 2454, 2021 | 65 | 2021 |
| CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication P Tebas, JK Jadlowsky, PA Shaw, L Tian, E Esparza, AL Brennan, S Kim, ... The Journal of clinical investigation 131 (7), 2021 | 64 | 2021 |
| Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption MVP Gondim, S Sherrill-Mix, F Bibollet-Ruche, RM Russell, S Trimboli, ... Science translational medicine 13 (576), eabd8179, 2021 | 64 | 2021 |
| A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia KJ Bar, PA Shaw, GH Choi, N Aqui, A Fesnak, JB Yang, H Soto-Calderon, ... The Journal of clinical investigation 131 (24), 2021 | 63 | 2021 |
